27552906|t|Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort(®) Turbuhaler(®) dry powder fixed combination aerosol drug
27552906|a|One of the most widespread dry powder fixed combinations used in asthma and chronic obstructive pulmonary disease (COPD) management is Symbicort(®) Turbuhaler(®). The aim of this study was to simulate the deposition distribution of both components of this drug within the airways based on realistic airflow measurements. Breathing parameters of 25 healthy adults (11 females and 14 males) were acquired while inhaling through Turbuhaler(®). Individual specific emitted doses and particle size distributions of Symbicort(®) Turbuhaler(®) were determined. A self-developed particle deposition model was adapted and validated to simulate the deposition of budesonide (inhaled corticosteroid; ICS) and formoterol (long acting β2 agonist; LABA) in the upper airways and lungs of the healthy volunteers. Based on current simulations the emitted doses varied between 50.4% and 92.5% of the metered dose for the ICS, and between 38% and 96.1% in case of LABA component depending on the individual inhalation flow rate. This variability induced a notable inter- individual spread of the deposited lung doses (mean: 33.6%, range: 20.4%-48.8% for budesonide and mean: 29.8%, range: 16.4%-42.9% for formoterol). Significant inter-gender differences were also observed. Average lung dose of budesonide was 29.2% of the metered dose for females and 37% for males, while formoterol deposited with 26.4% efficiency for females and 32.5% for males. Present results also highlighted the importance of breath-holding after inhalation of the drug. About a half of the total lung deposition occurred during breath-hold at 9.6s average breath-hold time. Calculated depositions confirmed appropriate lung deposition of Symbicort(®) Turbuhaler(®) for both genders, however more effort for optimal inhalation technique is advised for persons with low vital capacity. This study demonstrated the possibility of personalized prediction of airway deposition of aerosol drugs by numerical simulations. The methodology developed in this study will be applicable also to other marketed drugs in the future.
27552906	0	20	Numerical simulation	T062	UMLS:C0679083
27552906	24	40	emitted particle	T103	UMLS:C0597177
27552906	61	67	airway	T017	UMLS:C0458827
27552906	79	91	distribution	T038	UMLS:C1378698
27552906	95	121	Symbicort(®) Turbuhaler(®)	T103	UMLS:C1735945
27552906	122	132	dry powder	T103	UMLS:C0032861
27552906	139	150	combination	T103	UMLS:C0013162
27552906	151	163	aerosol drug	T103	UMLS:C1112870
27552906	191	201	dry powder	T103	UMLS:C0032861
27552906	208	220	combinations	T103	UMLS:C0013162
27552906	229	235	asthma	T038	UMLS:C0004096
27552906	240	277	chronic obstructive pulmonary disease	T038	UMLS:C0024117
27552906	279	283	COPD	T038	UMLS:C0024117
27552906	285	295	management	T058	UMLS:C0376636
27552906	299	325	Symbicort(®) Turbuhaler(®)	T103	UMLS:C1735945
27552906	343	348	study	T062	UMLS:C2603343
27552906	356	364	simulate	T062	UMLS:C0679083
27552906	380	392	distribution	T038	UMLS:C1378698
27552906	420	424	drug	T103	UMLS:C1254351
27552906	436	443	airways	T017	UMLS:C0458827
27552906	485	494	Breathing	T038	UMLS:C0004048
27552906	512	526	healthy adults	T033	UMLS:C0686750
27552906	573	581	inhaling	T038	UMLS:C0004048
27552906	590	603	Turbuhaler(®)	T074	UMLS:C1553479
27552906	605	615	Individual	T098	UMLS:C0027361
27552906	657	670	distributions	T038	UMLS:C1378698
27552906	674	700	Symbicort(®) Turbuhaler(®)	T103	UMLS:C1735945
27552906	735	743	particle	T103	UMLS:C0597177
27552906	755	760	model	T170	UMLS:C3161035
27552906	790	798	simulate	T062	UMLS:C0679083
27552906	817	827	budesonide	T103	UMLS:C0054201
27552906	829	851	inhaled corticosteroid	T103	UMLS:C1629043
27552906	853	856	ICS	T103	UMLS:C1629043
27552906	862	872	formoterol	T103	UMLS:C0060657
27552906	874	896	long acting β2 agonist	T103	UMLS:C2987634
27552906	898	902	LABA	T103	UMLS:C2987634
27552906	911	924	upper airways	T082	UMLS:C0225377
27552906	929	934	lungs	T017	UMLS:C0024109
27552906	942	960	healthy volunteers	T098	UMLS:C1708335
27552906	979	990	simulations	T062	UMLS:C0679083
27552906	1068	1071	ICS	T103	UMLS:C1629043
27552906	1110	1114	LABA	T103	UMLS:C2987634
27552906	1142	1152	individual	T098	UMLS:C0027361
27552906	1153	1173	inhalation flow rate	T201	UMLS:C0231832
27552906	1217	1227	individual	T098	UMLS:C0027361
27552906	1252	1256	lung	T017	UMLS:C0024109
27552906	1300	1310	budesonide	T103	UMLS:C0054201
27552906	1351	1361	formoterol	T103	UMLS:C0060657
27552906	1429	1433	lung	T017	UMLS:C0024109
27552906	1442	1452	budesonide	T103	UMLS:C0054201
27552906	1520	1530	formoterol	T103	UMLS:C0060657
27552906	1647	1661	breath-holding	T033	UMLS:C0235744
27552906	1668	1678	inhalation	T038	UMLS:C0004048
27552906	1686	1690	drug	T103	UMLS:C1254351
27552906	1718	1722	lung	T017	UMLS:C0024109
27552906	1750	1761	breath-hold	T033	UMLS:C0235744
27552906	1778	1789	breath-hold	T033	UMLS:C0235744
27552906	1841	1845	lung	T017	UMLS:C0024109
27552906	1860	1886	Symbicort(®) Turbuhaler(®)	T103	UMLS:C1735945
27552906	1929	1957	optimal inhalation technique	T058	UMLS:C1998547
27552906	1973	1980	persons	T098	UMLS:C0027361
27552906	1986	2004	low vital capacity	T033	UMLS:C0476408
27552906	2011	2016	study	T062	UMLS:C2603343
27552906	2076	2082	airway	T017	UMLS:C0458827
27552906	2097	2110	aerosol drugs	T103	UMLS:C1112870
27552906	2114	2135	numerical simulations	T062	UMLS:C0679083
27552906	2171	2176	study	T062	UMLS:C2603343
27552906	2219	2224	drugs	T103	UMLS:C1254351